Ozempic 1mg/3ml 1 Pen by Novo Nordisk

Usage

1. Retrieve the Ozempic pen from refrigerator storage (2–8 °C) at least 30 minutes before injection to allow the solution to reach room temperature — cold injection increases local discomfort at the GLP-1 receptor-stimulated injection site.
2. Inspect the solution visually: semaglutide solution should be clear and colourless to slightly yellow; do not use if particulates or cloudiness are present, as degradation compromises receptor binding integrity.
3. Attach a new NovoFine or compatible pen needle by screwing it on until secure; perform a small air-shot to confirm pen flow — this step is critical with prefilled incretin pens to avoid air-bubble dosing errors.
4. Dial the prescribed dose (0.25 mg, 0.5 mg, or 1 mg) by turning the dose selector until the correct number aligns with the pointer — the incremental dial prevents accidental over-dosing during the GLP-1 titration phase.
5. Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites weekly to prevent lipohypertrophy, which can impair semaglutide absorption and blunt GLP-1 receptor-mediated glucose response.
6. After injection, hold the pen in place for 6 seconds before withdrawing to ensure full dose delivery, then remove and safely dispose of the needle; record the date of first use and ensure the pen is used within 56 days.

Warnings

Frequently asked questions

How does GLP-1 receptor agonism actually produce weight loss in the body?

GLP-1 receptor agonists like semaglutide reduce body weight through two converging mechanisms: central appetite suppression via hypothalamic GLP-1 receptors and peripheral slowing of gastric emptying that prolongs satiety signals. In the SUSTAIN 8 trial, semaglutide 1 mg produced a mean weight reduction of approximately 5.5 kg over 56 weeks compared to 1.9 kg with canagliflozin, illustrating the magnitude of incretin-driven weight effect.

What distinguishes GLP-1 receptor agonism from GIP receptor agonism at the molecular level?

GLP-1 and GIP receptors are both Class B G-protein-coupled receptors but couple to overlapping yet distinct downstream effectors. GLP-1 receptor activation dominantly drives cAMP-mediated insulin secretion and appetite suppression, while GIP receptor activation additionally engages adipocyte pathways involved in lipid storage. Semaglutide acts solely on GLP-1 receptors, giving it a cleaner, more extensively studied pharmacological profile versus dual GLP-1/GIP co-agonists.

Why does semaglutide slow gastric emptying, and does this effect persist long term?

Semaglutide slows gastric emptying by activating GLP-1 receptors on vagal afferents and enteric neurons, reducing antral contractility and pyloric tone. Clinical data from paracetamol absorption studies show this effect is most pronounced in the first weeks of treatment and attenuates partially over time — a phenomenon sometimes called tachyphylaxis of the gastric-emptying effect — while glycaemic and weight benefits are maintained, suggesting alternative mechanisms sustain the therapeutic outcome.

How should the Ozempic 1mg/3ml prefilled pen be stored and how long is it usable after first use?

Before first use, Ozempic pens must be stored in a refrigerator at 2–8 °C away from the freezing element. Once the pen is in use, it can be kept at room temperature (below 30 °C) or refrigerated for up to 56 days (8 weeks). Never freeze a pen that has been opened, as freezing degrades the semaglutide solution and invalidates dose accuracy.

Why is the 1mg/3ml concentration considered the entry-level dose in the Ozempic pen range, and how is dosing dialled in?

The 1 mg/3 ml pen contains the lowest commercially available semaglutide concentration in the Ozempic range, making it the preferred option during the mandatory dose-escalation phase — starting at 0.25 mg once weekly for four weeks, then 0.5 mg, before reaching the 1 mg maintenance dose. The pen's dial mechanism allows the prescriber-directed dose to be set precisely without reconstitution or syringe measurement, minimising injection error. (2) angle_used

Manufacturer

Novo Nordisk's journey into metabolic medicine began more than a century ago in Denmark, rooted initially in insulin production at a time when diabetes treatment options were virtually non-existent. Over subsequent decades, the company evolved from a Scandinavian pharmaceutical producer into one of the world's largest dedicated metabolic-disease specialists, with manufacturing infrastructure spanning Kalundborg, Denmark — one of the world's single largest pharmaceutical production sites by output volume. The development of semaglutide represents the culmination of Novo Nordisk's incretin research programme, which dates to the early 2000s and built directly on foundational academic work mapping the GLP-1 receptor's structure and signalling pathways. Ozempic's path from molecule to market involved the landmark SUSTAIN clinical programme — eight large-scale Phase III randomised controlled trials enrolling tens of thousands of patients globally — a regulatory and scientific investment that positioned semaglutide as the reference molecule against which subsequent GLP-1 and dual incretin agonists are benchmarked. Novo Nordisk manufactures Ozempic under EU GMP Annex 1 aseptic conditions, with each production batch subject to HPLC purity verification, LAL endotoxin clearance testing, and pharmacopoeial sterility assurance before release.